ArticleBMC infectious diseases2019
Prevalence and capsular type distribution of Streptococcus agalactiae isolated from pregnant women in Namibia and South Africa.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Maternal and Newborn Group BOpen forum infectious diseases · 2026Article
- Atypical detection of group B Streptococcus ST - 17 clone from a diabetic patient with necrotising fasciitis: A case report.IDCases · 2026Article
- A large prospective study of group B Streptococcus carriage in pregnant women in Morocco: prevalence, serotype distribution, antimicrobial resistance and virulence determinants.BMC infectious diseases · 2025Article
- Streptococcus agalactiae colonization is common among pregnant women with HIV infection and is neither predicted by hospital tier nor trimester in Mwanza, Tanzania.BMC pregnancy and childbirth · 2025Article
- Group B streptococcal infections in pregnancy and early life.Clinical microbiology reviews · 2025Review
- Screening of Group BOpen medicine (Warsaw, Poland) · 2025Review
- Stillbirths and Neonatal Deaths Caused by Group BOpen forum infectious diseases · 2023Article
- Distribution and Prevalence of Serotypes of Group BMaternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2023Article
- Group B Streptococcal Colonization among Pregnant Women and Neonates in a Tertiary Care Hospital in South India.Indian journal of pediatrics · 2022Article
- Group B Streptococcal Colonization in African Countries: Prevalence, Capsular Serotypes, and Molecular Sequence Types.Pathogens (Basel, Switzerland) · 2021Review
- Group B Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at Adama Hospital Medical College, Ethiopia.Scientific reports · 2020Article
- Prevalence and capsular type distribution of group BIranian journal of microbiology · 2020Article
- Antibiotic Resistance and Molecular Epidemiological Characteristics ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020Article
- Genomic Insights Into the Distribution and Evolution of Group B Streptococcus.Frontiers in microbiology · 2019Review
- Prevalence, risk factors, and serotypes of group BTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptococcus agalactiae or Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality resulting in septicaemia, bacteraemia and meningitis. Long term problems in children range from loss of hearing to mental retardation. While Intrapartum Antibiotic Prophylaxis (IAP) has reduced the incidence of S. agalactiae infection, it still remains the leading cause of disease in neonates. GBS has ten capsular types whose distribution varies across the world. Therefore, this study sought to determine the prevalence of GBS in Namibia and South Africa amongst pregnant women between 35 and 37 weeks gestation and elucidate the capsular types.
methodsLower vaginal and rectal swabs were collected from pregnant women between 35 and 37 weeks gestation. Five hundred and thirty pregnant women were recruited into the study in Windhoek, Namibia while one hundred pregnant women were recruited in the Eastern Cape, South Africa. The swabs were cultured on 5% sheep blood agar (Biomerieux, New Jersey, USA) for isolation of GBS. Presumptive isolates were confirmed using both the Vitek (2) and molecular techniques targeting the scpB gene. Capsular typing was performed in a multiplex PCR with capsular specific primer pairs.
resultsThe prevalence of GBS in Namibia was 13.6 and 37% in South Africa respectively. In both countries most women were dually colonised with GBS. Capsular types II, III and V were the most prevalent.
conclusionsThe prevalence of GBS in Namibia was lower than in South Africa in this study. The prevalence in both countries was not different from those reported in other African countries and around the world. The predominant capsular types in this study are the ones commonly associated with adverse maternal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.